Comparative Outcomes of Meropenem–Vaborbactam vs. Ceftazidime–Avibactam Among Adults Hospitalized with an Infectious Syndrome in the US, 2019–2021

<b>Background/Objectives</b>: Meropenem–vaborbactam (MEV) and ceftazidime–avibactam (CZA) are active against “urgent threat” pathogens like carbapenem-resistant Enterobacterales (CRE). However, few studies have compared outcomes between them. <b>Methods</b>: To explore comparative outcomes of MEV vs...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Marya D. Zilberberg, Brian H. Nathanson, Mark A. Redell, Kate Sulham, Andrew F. Shorr
Format:	Artigo
Jezik:	Inglês
Izdano:	MDPI AG 2025-01-01
Serija:	Antibiotics
Teme:	comparative outcomes multidrug resistance hospitalization outcomes epidemiology
Online dostop:	https://www.mdpi.com/2079-6382/14/1/29
Oznake:	Označite Brez oznak, prvi označite!